Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
Standard
Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. / Rawnaq, Tamina; Kunkel, Miriam; Bachmann, Kai; Simon, Ronald; Zander, Hilke; Brandl, Stephan; Sauter, Guido; Izbicki, Jakob R.; Kaifi, Jussuf.
In: ANN SURG ONCOL, Vol. 18, No. 2, 2, 2011, p. 559-565.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
AU - Rawnaq, Tamina
AU - Kunkel, Miriam
AU - Bachmann, Kai
AU - Simon, Ronald
AU - Zander, Hilke
AU - Brandl, Stephan
AU - Sauter, Guido
AU - Izbicki, Jakob R.
AU - Kaifi, Jussuf
PY - 2011
Y1 - 2011
N2 - A previous study identified midkine (MK) expression in primary gastrointestinal stromal tumor (GIST) as a prognostic marker. The aim of the current study was to compare serum midkine (S-MK) concentrations of GIST patients with those of healthy controls and to determine if MK can serve as a prognostic serum marker for these patients.
AB - A previous study identified midkine (MK) expression in primary gastrointestinal stromal tumor (GIST) as a prognostic marker. The aim of the current study was to compare serum midkine (S-MK) concentrations of GIST patients with those of healthy controls and to determine if MK can serve as a prognostic serum marker for these patients.
M3 - SCORING: Journal article
VL - 18
SP - 559
EP - 565
JO - ANN SURG ONCOL
JF - ANN SURG ONCOL
SN - 1068-9265
IS - 2
M1 - 2
ER -